These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson's Disease. Pedroso I; Garcia M; Casabona E; Morales L; Bringas ML; Pérez L; Rodríguez T; Sosa I; Ricardo Y; Padrón A; Amaro D Behav Sci (Basel); 2018 May; 8(5):51. PubMed ID: 29862060 [No Abstract] [Full Text] [Related]
6. The Effect of Neuroepo on Cognition in Parkinson's Disease Patients Is Mediated by Electroencephalogram Source Activity. Bringas Vega ML; Pedroso Ibáñez I; Razzaq FA; Zhang M; Morales Chacón L; Ren P; Galan Garcia L; Gan P; Virues Alba T; Lopez Naranjo C; Jahanshahi M; Bosch-Bayard J; Valdes-Sosa PA Front Neurosci; 2022; 16():841428. PubMed ID: 35844232 [TBL] [Abstract][Full Text] [Related]
7. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Ehrenreich H; Weissenborn K; Prange H; Schneider D; Weimar C; Wartenberg K; Schellinger PD; Bohn M; Becker H; Wegrzyn M; Jähnig P; Herrmann M; Knauth M; Bähr M; Heide W; Wagner A; Schwab S; Reichmann H; Schwendemann G; Dengler R; Kastrup A; Bartels C; Stroke; 2009 Dec; 40(12):e647-56. PubMed ID: 19834012 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of iorEPOCIM for chemotherapy- or radiotherapy-induced anemia in pediatric cancer patients. Vargas A; Mendoza I; Uranga R; González A; Martínez L; Caballero I; Piedra P; Saurez G; Verdecia M; Cabanas R MEDICC Rev; 2010 Jul; 12(3):27-31. PubMed ID: 20697335 [TBL] [Abstract][Full Text] [Related]
10. Neuroprotective Effects of neuroEPO Using an In Vitro Model of Stroke. Fernando G; Yamila R; Cesar GJ; Ramón R Behav Sci (Basel); 2018 Feb; 8(2):. PubMed ID: 29438293 [TBL] [Abstract][Full Text] [Related]
11. Intranasal erythropoietin therapy in nervous system disorders. Genc S; Zadeoglulari Z; Oner MG; Genc K; Digicaylioglu M Expert Opin Drug Deliv; 2011 Jan; 8(1):19-32. PubMed ID: 21143002 [TBL] [Abstract][Full Text] [Related]
12. The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans. Garcia-Rodriguez JC; Sosa-Teste I ScientificWorldJournal; 2009 Sep; 9():970-81. PubMed ID: 19768354 [TBL] [Abstract][Full Text] [Related]
13. Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease. Maurice T; Mustafa MH; Desrumaux C; Keller E; Naert G; de la C García-Barceló M; Rodríguez Cruz Y; Garcia Rodríguez JC J Psychopharmacol; 2013 Nov; 27(11):1044-57. PubMed ID: 23813967 [TBL] [Abstract][Full Text] [Related]
15. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study. Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA; BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687 [TBL] [Abstract][Full Text] [Related]
16. Absence of hematological side effects in acute and subacute nasal dosing of erythropoietin with a low content of sialic acid. Lagarto A; Bueno V; Guerra I; Valdés O; Couret M; López R; Vega Y Exp Toxicol Pathol; 2011 Sep; 63(6):563-7. PubMed ID: 20488687 [TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. Miskowiak KW; Vinberg M; Christensen EM; Bukh JD; Harmer CJ; Ehrenreich H; Kessing LV Neuropsychopharmacology; 2014 May; 39(6):1399-408. PubMed ID: 24322509 [TBL] [Abstract][Full Text] [Related]
18. Nasal neuro EPO could be a reliable choice for neuroprotective stroke treatment. Parra AL; Rodriguez JC Cent Nerv Syst Agents Med Chem; 2012 Mar; 12(1):60-8. PubMed ID: 22376076 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C; Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606 [TBL] [Abstract][Full Text] [Related]
20. Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study. Novak P; Pimentel Maldonado DA; Novak V PLoS One; 2019; 14(4):e0214364. PubMed ID: 31022213 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]